GlassScriptPhysician profile
Alejandro Bustamante
NPI 1407058142
$2,306.88
in general payments reported to CMS, 2019-2025
31 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $146 · 2021: $341 · 2022: $524 · 2023: $606 · 2024: $586 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.68 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.16 | 2021-2023 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $363.57 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $238.54 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $180.64 | 2021-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $93.38 | 2021-2023 | |
| Abbott Laboratories | $92.66 | 2023-2025 | Armada, Eterna, Supera |
| Merck Sharp & Dohme LLC | $91.72 | 2020-2023 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Corium, LLC | $90.21 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $70.78 | 2021-2025 | Wegovy |
| Amgen INC. | $57.78 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $43.88 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $41.55 | 2021 | |
| Glaxosmithkline, LLC. | $38.84 | 2020-2023 | Trelegy Ellipta |
| Abiomed | $35.72 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $33.71 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $32.49 | 2021 | |
| Edwards Lifesciences Corporation | $30.06 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $29.64 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $28.14 | 2020 | |
| Seqirus USA INC | $26.98 | 2024 | Flucelvax, Fluad |
| Astellas Pharma US INC | $26.12 | 2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $24.44 | 2022 | |
| Sanofi Pasteur INC. | $21.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.33 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $20.88 | 2023 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.37 | 2021 | |
| Lucid Diagnostics INC. | $18.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.12 | 2023 | |
| Redhill Biopharma INC. | $16.56 | 2021 | |
| Cranial Technologies, INC | $15.54 | 2020 | |
| Amarin Pharma, INC. | $14.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Bustamante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.